Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study

Journal of the European Academy of Dermatology and Venereology, Год журнала: 2024, Номер 38(9), С. 1799 - 1808

Опубликована: Янв. 29, 2024

There is limited epidemiological evidence on outcomes associated with dupilumab exposure during pregnancy; monitoring pregnancy in large populations required.

Язык: Английский

---

Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(2), С. 1042 - 1042

Опубликована: Янв. 15, 2024

Psoriasis and atopic dermatitis fall within the category of cutaneous immune-mediated inflammatory diseases (IMIDs). The prevalence IMIDs is increasing in industrialized societies, influenced by both environmental changes a genetic predisposition. However, exact immune factors driving these chronic, progressive are not fully understood. By using multi-omics techniques IMIDs, it expected to advance understanding skin biology, uncover underlying mechanisms conditions, potentially devise precise personalized approaches diagnosis treatment. We provide narrative review current knowledge genomics, epigenomics, proteomics psoriasis. A literature search was performed for articles published until 30 November 2023. Although there still much uncover, recent evidence has already provided valuable insights, such as proteomic profiles that permit differentiating psoriasis from mycosis fungoides β-defensin 2 correlation PASI its drop due secukinumab first injection, among others.

Язык: Английский

---

Atopic Dermatitis in the Elderly Population

Acta Dermato Venereologica, Год журнала: 2023, Номер 103, С. adv13363 - adv13363

Опубликована: Дек. 14, 2023

Atopic dermatitis is a common inflammatory disease with chronic and relapsing course. Although considered childhood disease, it now evident that atopic also in adulthood the elderly population. typically manifests bilateral symmetrical eczematous lesions on face, trunk skin folds. Itch invariably present may be very severe, markedly affecting daily life sleep. In older adults, have high level of impact quality life, frequently burdening an already complex comorbid situation. The full assessment burden (localizations, itch severity, sleep alterations, history, comorbidities) crucial to identify most appropriate treatment. many cases, moderate-to-severe population can successfully safely treated biological agents inhibiting interleukin-4/-13 pathway, whereas use Janus kinase inhibitors pose concerns about safety profile.

Язык: Английский

---

Safety of dupilumab in patients with cancer

Journal of the European Academy of Dermatology and Venereology, Год журнала: 2024, Номер 38(9)

Опубликована: Фев. 19, 2024

Язык: Английский

---

A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis

Dermatology and Therapy, Год журнала: 2024, Номер 14(6), С. 1443 - 1455

Опубликована: Май 30, 2024

Atopic dermatitis (AD) is a highly heterogeneous chronic inflammatory skin disorder that frequently associated with plethora of comorbidities. AD is, therefore, considered systemic disease impacted by considerable burden and leading to poor quality life, especially in patients moderate-to-severe disease. Since atopic non-atopic comorbidities can further worsen the course, accurate establishment patient's individual intrinsic risk profile needs crucial may help guiding selection best treatment option. Better care for be delivered through multidisciplinary team led dermatologist, comprehensive patient management. The implementation approach could enhance delivery optimised safe treatments, improve standard outcomes short long term, prevent or delay lifelong impact uncontrolled AD. Understanding unmet needs, assessing correctly enhancing shared patient–physician decision-making process lead control quality-of-life improvement, context introduction newer This narrative review call more data establish standardised profiles strategies In view on fast-evolving treatments AD, this aims at highlighting importance assessment holistic

Язык: Английский

---

The last step to achieve barrier damage control

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Фев. 13, 2024

Heterogeneity characterises inflammatory diseases and different phenotypes endotypes have been identified. Both innate adaptive immunity contribute to the immunopathological mechanism of these barrier damage plays a prominent role triggering type 2 inflammation through alarmins system, such as anti-Thymic Stromal Lymphopoietin (TSLP). Treatment with anti-TSLP monoclonal antibodies showed efficacy in severe asthma clinical trials for other eosinophilic are ongoing. The aim this perspective review is analyse current advances future applications TSLP inhibition control damage.

Язык: Английский

---

Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study)

Journal of the European Academy of Dermatology and Venereology, Год журнала: 2024, Номер 38(11), С. 2149 - 2155

Опубликована: Июль 17, 2024

Clinical trials and real-life data have reported an increased incidence of conjunctivitis in patients treated with dupilumab for their atopic dermatitis (AD). Although mostly mild severity, some cases will appear or increase after initiation, which can lead to discontinuation.

Язык: Английский

---

A Pediatric Case of Severe Atopic Dermatitis on Dupilumab Treatment and Pulmonary Tuberculosis

Pediatric Dermatology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 29, 2025

Atopic dermatitis (AD) is a common disease affecting nearly 20% of the pediatric population in developed countries. The use biologic therapies, such as dupilumab, has considerably changed treatment AD. However, effects drugs on immune system may raise doubts and concerns, particularly special populations, like those with active or latent infections [1]. Here, we present case patient AD who was found to be infected Mycobacterium tuberculosis during dupilumab. Our 12-year-old boy suffered from severe since age 1 year been dupilumab for past 2 years. Prior this, he had treated topical steroids, tacrolimus, systemic ciclosporin. Before starting his EASI score ranged between 30 35, experienced itching, significant impact quality life. Additionally, hospitalized twice impetiginization lesions, which benzylpenicillin. At time this report, receiving 200 mg month. He screened, mother diagnosed smear negative pleuro-pulmonary (TB), resulting positive interferon-gamma release assay tuberculin skin test. Therefore, chest radiograph CT scan were performed, showing pulmonary lymphadenopathy reticular pattern tree-in-bud sign. isoniazid, rifampicin, pyrazinamide, ethambutol months plus an additional isoniazid accordance 4-month short-treatment protocol indicated uncomplicated form [2]. In agreement infectious diseases specialists managing patient, decided continue therapy Follow-up evaluations conducted monthly over period 6 months. Throughout period, did not experience any cutaneous adverse effects, TB carried out successfully. A performed at end normal. Dupilumab, antibody targeting interleukin-4 receptor alpha (IL-4Rα), approved aged older. Biologics IL-13/IL- 4Rα axis are apparently able compromise integrity tubercular granulomas, making bacterial reactivation very unlikely [3]. Consequently, screening required prior initiation therapy. recent expert consensus stated that JAK-inhibitors traditional drugs, methotrexate cyclosporine, should avoided patients untreated infection, while biologics AD, represent preferred option Moreover, two cases bullous pemphigoid one pemphigus vulgaris off-label started without complication further support notion safe particular group [4, 5]. conclusion, seems viable alternative TB. studies needed confirm its safety population. authors declare no conflicts interest. manuscript have given written informed consent publication their details. data findings study available corresponding author upon reasonable request.

Язык: Английский

---

Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review

Clinical Cosmetic and Investigational Dermatology, Год журнала: 2025, Номер Volume 18, С. 311 - 317

Опубликована: Янв. 1, 2025

Atopic dermatitis (AD) and pruritic skin disorders are increasingly recognized in cancer patients. The management of these conditions patients with a history or concomitant presents unique challenges, as traditional systemic therapies may pose risks due to their immunosuppressive effects. In recent years, biologic agents such dupilumab tralokinumab have emerged promising treatments for AD, offering targeted modulation the immune response potentially fewer side This article aims review current evidence on safety efficacy treating AD pruritus among survivors, addressing potential benefits considerations this patient population. A comprehensive analysis medical literature was performed PubMed, Ovid, Scopus, Embase, Cochrane Library databases until December 15, 2024. conducting narrative review, Medical Subject Headings (MeSH) terms terminology related clinical trials real-life studies were employed, focusing pharmacological dupilumab, tralokinumab. Patients active past typically excluded from new medications, complicating evaluation progression recurrence setting. use drugs like oncological marks significant breakthrough eczema pruritus, which common group. Although there no explicit contraindications using malignancy, is definitive guidance cases. Real-world data emerging, facilitated by collaboration between dermatologists oncologists, supporting effectiveness managing Nonetheless, larger longer follow-up periods dedicated pharmacovigilance programs needed substantiate findings.

Язык: Английский

---

Functional Magnetic Resonance Imaging in Prurigo Nodularis: A Systematic Review

Clinics in Dermatology, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

---